JP2002515511A - 放射線及び成長因子レセプター・チロシン・キナーゼのインヒビターを使用するヒト腫瘍の治療 - Google Patents

放射線及び成長因子レセプター・チロシン・キナーゼのインヒビターを使用するヒト腫瘍の治療

Info

Publication number
JP2002515511A
JP2002515511A JP2000549641A JP2000549641A JP2002515511A JP 2002515511 A JP2002515511 A JP 2002515511A JP 2000549641 A JP2000549641 A JP 2000549641A JP 2000549641 A JP2000549641 A JP 2000549641A JP 2002515511 A JP2002515511 A JP 2002515511A
Authority
JP
Japan
Prior art keywords
antibody
egfr
family
tyrosine kinase
receptor tyrosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000549641A
Other languages
English (en)
Japanese (ja)
Inventor
ダブリュ． ワクサル，ハーラン
エヌ． サレー，マンスーア
ロバート，フランシスコ
ジェイ ブックスバウム，ドナルド
Original Assignee
イムクローン システムズ インコーポレイティド
ユーエービー リサーチ ファウンデイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イムクローン システムズ インコーポレイティド, ユーエービー リサーチ ファウンデイション filed Critical イムクローン システムズ インコーポレイティド
Publication of JP2002515511A publication Critical patent/JP2002515511A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2000549641A 1998-05-15 1999-05-14 放射線及び成長因子レセプター・チロシン・キナーゼのインヒビターを使用するヒト腫瘍の治療 Pending JP2002515511A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US8561398P 1998-05-15 1998-05-15
US7961298A 1998-05-15 1998-05-15
US60/085,613 1998-05-15
US09/079,612 1998-05-15
US20613898A 1998-12-07 1998-12-07
US09/206,138 1998-12-07
PCT/US1999/010741 WO1999060023A1 (en) 1998-05-15 1999-05-14 Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases

Publications (1)

Publication Number Publication Date
JP2002515511A true JP2002515511A (ja) 2002-05-28

Family

ID=27373511

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000549641A Pending JP2002515511A (ja) 1998-05-15 1999-05-14 放射線及び成長因子レセプター・チロシン・キナーゼのインヒビターを使用するヒト腫瘍の治療

Country Status (14)

Country Link
EP (1) EP1080113A4 (xx)
JP (1) JP2002515511A (xx)
KR (1) KR20010071271A (xx)
CN (1) CN1314917A (xx)
AU (1) AU4079999A (xx)
BR (1) BR9910511A (xx)
CA (1) CA2332331A1 (xx)
CZ (1) CZ20004224A3 (xx)
HK (1) HK1040720A1 (xx)
IL (1) IL139707A0 (xx)
MX (1) MXPA00011248A (xx)
PL (1) PL348634A1 (xx)
SK (1) SK17282000A3 (xx)
WO (1) WO1999060023A1 (xx)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008500815A (ja) * 2004-03-19 2008-01-17 イムクローン システムズ インコーポレイティド ヒト抗上皮成長因子受容体抗体
JP2015509944A (ja) * 2012-02-23 2015-04-02 ユー３・ファーマ・ゲーエムベーハー 放射線感受性を調節するためのｈｅｒ３阻害剤

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
EP1745799B1 (en) 1998-03-04 2015-09-02 The Trustees of The University of Pennsylvania Compositions and methods of treating tumors
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
AU780454B2 (en) 1999-06-03 2005-03-24 Jessie L.S. Au Methods and compositions for modulating cell proliferation and cell death
GB9925958D0 (en) * 1999-11-02 1999-12-29 Bundred Nigel J Therapeutic use
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
WO2002011677A2 (en) * 2000-08-09 2002-02-14 Imclone Systems Incorporated Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
AU2002239486A1 (en) * 2000-12-08 2002-06-18 Uab Research Foundation Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody
CU22979A1 (es) * 2000-12-08 2004-09-09 Centro Inmunologia Molecular Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
US7081454B2 (en) 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
AU2003213687A1 (en) 2002-03-04 2003-09-22 Imclone Systems Incorporated Human antibodies specific to kdr and uses thereof
ES2299692T3 (es) * 2002-04-02 2008-06-01 Nerviano Medical Sciences S.R.L. Terapia combinada contra tumores que comprende derivados de distmicina acriloil sustituido y radioterapia.
US7217796B2 (en) 2002-05-24 2007-05-15 Schering Corporation Neutralizing human anti-IGFR antibody
ES2527871T3 (es) 2003-05-01 2015-02-02 Imclone Llc Anticuerpos completamente humanos dirigidos contra el receptor del factor de crecimiento 1 similar a la insulina humana
CN101966338A (zh) 2003-06-09 2011-02-09 塞缪尔·瓦克萨尔 用胞外拮抗物和胞内拮抗物抑制受体酪氨酸激酶的方法
US7312215B2 (en) 2003-07-29 2007-12-25 Bristol-Myers Squibb Company Benzimidazole C-2 heterocycles as kinase inhibitors
JP4638870B2 (ja) 2003-08-13 2011-02-23 ファイザー・プロダクツ・インク 修飾ヒトｉｇｆ−１ｒ抗体
US7326567B2 (en) 2003-11-12 2008-02-05 Schering Corporation Plasmid system for multigene expression
PE20050928A1 (es) 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
NZ551431A (en) 2004-06-03 2010-04-30 Hoffmann La Roche Treatment with cisplatin and an EGFR-inhibitor
JP2008521907A (ja) 2004-12-03 2008-06-26 シェーリング コーポレイション 抗ｉｇｆ１ｒ治療について患者を予め選択するためのバイオマーカー
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
BRPI0611984A2 (pt) 2005-06-17 2009-07-07 Imclone Systems Inc uso de anticorpos igf-ir para fabricação de um medicamento para tratar um tumor ósseo
JP5055284B2 (ja) 2005-09-20 2012-10-24 オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー インシュリン様成長因子−１受容体キナーゼ阻害剤に対する抗癌応答を予測する生物学的マーカー
US8236308B2 (en) 2005-10-11 2012-08-07 Micromet Ag Composition comprising cross-species-specific antibodies and uses thereof
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
WO2008022746A1 (en) 2006-08-21 2008-02-28 F. Hoffmann-La Roche Ag Tumor therapy with an anti-vegf antibody
EP3248617A3 (en) 2007-02-16 2018-02-21 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
MX2009010611A (es) * 2007-04-03 2010-03-26 Micromet Ag Enlazadores biespecificos, especificos para especies.
BRPI0816458A2 (pt) 2007-09-05 2013-03-12 Hoffmann La Roche terapia combinada com anticorpos anti-cd20 tipo i e tipo ii
US20090098118A1 (en) 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
AR071891A1 (es) 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
EP2318548B1 (en) 2008-08-15 2013-10-16 Merrimack Pharmaceuticals, Inc. Methods and systems for predicting response of cells to a therapeutic agent
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
WO2010099137A2 (en) 2009-02-26 2010-09-02 Osi Pharmaceuticals, Inc. In situ methods for monitoring the emt status of tumor cells in vivo
WO2010107968A1 (en) 2009-03-18 2010-09-23 Osi Pharmaceuticals, Inc. Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor
TWI461211B (zh) 2009-03-20 2014-11-21 Genentech Inc 抗－ｈｅｒ抗體
EP2236139A1 (en) 2009-03-31 2010-10-06 F. Hoffmann-La Roche AG Combination therapy of erlotinib with an anti-IGF-1R antibody, which does not inhibit binding of insulin to the insulin receptor
US20100247484A1 (en) 2009-03-31 2010-09-30 Heinrich Barchet Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3
TWI409079B (zh) 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
WO2011018225A1 (en) 2009-08-14 2011-02-17 Roche Glycart Ag Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
AU2011223643A1 (en) 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20110217309A1 (en) 2010-03-03 2011-09-08 Buck Elizabeth A Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
SG183532A1 (en) 2010-03-11 2012-09-27 Merrimack Pharmaceuticals Inc Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
CA2795544A1 (en) 2010-04-27 2011-11-03 Roche Glycart Ag Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor
TW201208703A (en) 2010-08-17 2012-03-01 Roche Glycart Ag Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
CN103261229A (zh) 2010-12-16 2013-08-21 罗切格利卡特公司 无岩藻糖基化cd20抗体与mdm2抑制剂的联合疗法
AU2012212075A1 (en) 2011-02-02 2013-07-18 Amgen Inc. Methods and compositons relating to inhibition of IGF-1R
WO2012116040A1 (en) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
AU2012239997A1 (en) 2011-04-07 2013-10-17 Amgen Inc. Novel EGFR binding proteins
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
AU2012335541B2 (en) 2011-11-11 2017-07-06 Duke University Combination drug therapy for the treatment of solid tumors
US20130302274A1 (en) 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
CA2884307A1 (en) 2012-09-07 2014-03-13 Genentech, Inc. Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
EP3122900A1 (en) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
PL3319995T3 (pl) 2015-07-07 2019-09-30 F. Hoffmann-La Roche Ag Terapia skojarzona z użyciem koniugatu przeciwciało anty-her2-lek i inhibitora bcl-2
EA201891304A1 (ru) 2015-12-03 2019-01-31 Агиос Фармасьютикалс, Инк. ИНГИБИТОРЫ MAT2A ДЛЯ ЛЕЧЕНИЯ MTAP-null ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ
US20190015393A1 (en) 2016-01-18 2019-01-17 Institut National De La Santé Et De La Recherche Médicale (Inserm) The use of a temporary inhibitor of p53 for preventing or reducing cancer relapse
CN109415441B (zh) 2016-05-24 2023-04-07 英斯梅德股份有限公司 抗体及其制备方法
WO2019020610A1 (en) 2017-07-26 2019-01-31 F. Hoffmann-La Roche Ag POLYTHERAPY USING BET INHIBITOR AND BCL-2 INHIBITOR
WO2019020606A1 (en) 2017-07-26 2019-01-31 F. Hoffmann-La Roche Ag POLYTHERAPY WITH BET INHIBITOR, BCL-2 INHIBITOR AND ANTI-CD20 ANTIBODY
TW201920282A (zh) * 2017-09-29 2019-06-01 中國大陸商上海藥明生物技術有限公司 抗egfr和pd-1的雙特異性抗體
EP3781139A1 (en) 2018-04-18 2021-02-24 F. Hoffmann-La Roche AG Combination therapy with a bet inhibitor and a proteasome inhibitor
WO2020234445A1 (en) 2019-05-23 2020-11-26 F. Hoffmann-La Roche Ag Combination therapy with a bet inhibitor and a bcl-2 inhibitor
WO2021155006A1 (en) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibitors of cyclin-dependent kinases and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
AU6267896A (en) * 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008500815A (ja) * 2004-03-19 2008-01-17 イムクローン システムズ インコーポレイティド ヒト抗上皮成長因子受容体抗体
JP4734319B2 (ja) * 2004-03-19 2011-07-27 イムクローン・リミテッド・ライアビリティ・カンパニー ヒト抗上皮成長因子受容体抗体
JP2015509944A (ja) * 2012-02-23 2015-04-02 ユー３・ファーマ・ゲーエムベーハー 放射線感受性を調節するためのｈｅｒ３阻害剤
JP2017165711A (ja) * 2012-02-23 2017-09-21 ダイイチサンキョウヨーロッパ ゲーエムベーハー 放射線感受性を調節するためのｈｅｒ３阻害剤
US10357566B2 (en) 2012-02-23 2019-07-23 Daiichi Sankyo Europe Gmbh HER3 inhibitor for modulating radiosensitivity
US11351259B2 (en) 2012-02-23 2022-06-07 Daiichi Sankyo Europe Gmbh HER3 inhibitor for modulating radiosensitivity

Also Published As

Publication number Publication date
SK17282000A3 (sk) 2002-04-04
CA2332331A1 (en) 1999-11-25
MXPA00011248A (es) 2004-09-06
CN1314917A (zh) 2001-09-26
EP1080113A1 (en) 2001-03-07
PL348634A1 (en) 2002-06-03
EP1080113A4 (en) 2002-04-17
BR9910511A (pt) 2001-11-20
IL139707A0 (en) 2002-02-10
AU4079999A (en) 1999-12-06
HK1040720A1 (zh) 2002-06-21
CZ20004224A3 (cs) 2002-02-13
WO1999060023A1 (en) 1999-11-25
KR20010071271A (ko) 2001-07-28

Similar Documents

Publication Publication Date Title
JP2002515511A (ja) 放射線及び成長因子レセプター・チロシン・キナーゼのインヒビターを使用するヒト腫瘍の治療
US20090297509A1 (en) Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
AU782994C (en) Treatment of refractory human tumors with epidermal growth factor receptor antagonists
EP0586002B1 (en) Monoclonal antibodies recognizing the epidermal growth factor receptor, cells and methods for their production and compositions containing them
EP2566895B1 (en) Anti-erbb3 antibodies
KR101683884B1 (ko) 항-ＥｐＣＡＭ 항체 및 이의 용도
KR20050057631A (ko) 2특이적 항-ｅｒｂ-ｂ 항체 및 종양 치료법에서의 이들의용도
RU2007133108A (ru) АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С EphA2, И МЕТОДЫ ИХ ИСПОЛЬЗОВАНИЯ
EP2288717B1 (en) Monoclonal antibodies to basic fibroblast growth factor
US20030202973A1 (en) Treatment of refractory human tumors with epidermal growth factor receptor and HER1 mitogenic ligand (EGFRML) antagonists
CN110563843A (zh) 一种靶向人vista蛋白的单克隆抗体
EP2337800B1 (en) Antibody combinations and use of same for treating cancer
US20150110788A1 (en) Bispecific antibodies with an fgf2 binding domain
CN110642950B (zh) 一种人源化t细胞活化的v域免疫抑制因子抗原结合片段
AU2004200705A1 (en) Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
CN114685674B (zh) 一种抗体融合蛋白及其应用
CN116419930A (zh) 结合her2的多价双特异性抗体、其制备方法和用途

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070703

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080108